

Chronic meralgia paresthetica and neurectomy

A clinical pathologic study



Sarah E. Berini, MD
Robert J. Spinner, MD
Mark E. Jentoft, MD
JaNean K. Engelstad, HT
Nathan P. Staff, MD
Narupat Suanprasert, MD
P. James B. Dyck, MD
Christopher J. Klein, MD

Correspondence to
Dr. Klein:
klein.christopher@mayo.edu

ABSTRACT

Objective: To understand the pathologic and clinical correlates of patients with chronic meralgia paresthetica (MP) undergoing lateral femoral cutaneous nerve (LFCN) neurectomy.

Methods: A retrospective cohort approach was utilized to identify 7 patients undergoing LFCN neurectomy for intractable pain. Control autopsied LFCN was obtained. Clinical, radiologic, and electrophysiologic features were reviewed.

Results: In identified cases, preoperative symptoms included severe lateral thigh pain and numbness. The duration of symptoms prior to surgery ranged from 2 to 15 years. Body mass index (BMI) varied from 20 kg/m² to 44.8 kg/m² (normal–morbidly obese), with 6 out of 7 patients being obese. No patients were diabetic. Focal nerve indentation at the inguinal ligament was seen intraoperatively and on gross pathology in 4 of 7 cases. Multifocal fiber loss, selective loss of large myelinated fibers, thinly myelinated profiles, regenerating nerve clusters, perineurial thickening, and subperineurial edema were seen. None of these features were observed in control nerve. Morphometric analysis confirmed loss of large myelinated fibers with small and intermediate size fiber predominance. Five patients had varying degrees of intraneural and epineurial inflammation. Six of 7 reported improved pain after neurectomy, sometimes dramatic.

Conclusions: Patients with chronic MP and intractable pain have an LFCN mononeuropathy with loss of nerve fibers. Pathologic and clinical study supports a compressive pathogenesis as the primary mechanism. Abnormal nerve inflammation coexists and may play a role in pathogenesis. These selected patients typically benefited from neurectomy at a site of inguinal ligament compression.

Classification of Evidence: This study provides Class IV evidence that patients with chronic MP LFCN neurectomy experience improvement in MP-related pain. *Neurology*® 2014;82:1551-1555

GLOSSARY

BMI = body mass index; **LFCN** = lateral femoral cutaneous nerve; **MP** = meralgia paresthetica.

Meralgia paresthetica (MP) has been found to be relatively common, with an incidence of 32.6–43 per 100,000 patient-years.^{1,2} The incidence is greatest in older persons (55–64 years) with elevated body mass index (BMI), which supports the theory that mechanical compression plays a role.¹ However, a strong association between diabetes and MP was also found, which was not explained by the increase in BMI alone, suggesting that diabetes may be an independent risk factor for MP. Specifically considered in the lateral femoral cutaneous nerve (LFCN), pathologic mechanisms of MP are (1) compression at the inguinal ligament from obesity; (2) injury susceptibility related to elevated blood sugars; or (3) an inflammatory or autoimmune mechanism as occurs in diabetic and nondiabetic lumbosacral plexitis, which commonly affects the femoral nerve.^{1,3}

Pathologic descriptions and the outcomes of patients undergoing neurectomy would provide great insight into the disease mechanism and is the objective of the presented work.

METHODS Standard protocol approvals, registrations, and patient consents. Approval for this study was received from our Institutional Review Board and Biospecimens Committee.

From the Peripheral Neuropathy Research Laboratory (S.E.B., J.K.E., N.P.S., N.S., P.J.B.D., C.J.K.), the Department of Neurosurgery (R.J.S.), and the Department of Anatomic Pathology (M.E.J.), Mayo Clinic and Mayo Foundation, Rochester, MN.

Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

Supplemental data
at Neurology.org

Primary research questions were as follows: (1) to assess the pathologic features of the LFCN and the clinical features of patients with severe and chronic MP; and (2) to retrospectively evaluate the effectiveness of LFCN neurectomy in treatment of chronic MP-related pain (Class IV evidence).

The medical charts of individuals undergoing open LFCN neurectomy proximal to the inguinal ligament for intractable pain were reviewed. An electronic retrieval system was utilized to assure all cases within the nerve pathology database were identified. Nine LFCNs were identified; 7 of these 9 cases were performed within our hospital system and had associated clinical and follow-up information. The clinical diagnosis of MP was confirmed in exclusion of alternative disorders such as neoplastic infiltration, acute nerve injury by external trauma, and upper lumbar radiculopathy. Age, sex, BMI, and diabetes status were determined. Available imaging and electrophysiology was reviewed. Because of the lack of normal values for the LFCN in terms of nerve morphology, fiber number, and distribution, a control LFCN from autopsy was obtained. Teased fiber, paraffin and epoxy sections, as well as morphometric procedures were performed by standard techniques.⁴ LFCN conduction studies were reviewed and performed by published technique.⁵

RESULTS Seven LFCN biopsies were identified from individuals undergoing neurectomy for intractable pain: 4 men and 3 women, age 27–78 years at the time of biopsy (table 1). Six patients had previously undergone ultrasound-guided steroid injections in proximity to the LFCN at the inguinal ligament with initial but unsustained benefit. BMIs ranged from 20.14 kg/m² to 44.81 kg/m² (normal to morbid obesity [>40 kg/m²]). Six out of the 7 patients had BMIs at or above 30 kg/m² (obese Class I). None of the patients was diabetic. Symptom duration at neurectomy ranged from 2 to 15 years. Six out of 7 patients had continuous painful lateral thigh numbness and paresthesias; 1 patient had intermittent symptoms,

severe on standing (case 1). Position-related pain occurred with standing (n = 5), lying (n = 2), or both (n = 1). Symptoms were unilateral in 5 and bilateral in 2 (cases 4 and 5). LFCN conductions were normal in 1 patient (case 1), unilaterally absent in 2 patients (cases 2 and 3), and bilaterally absent in 2 patients (cases 4 and 6). All patients underwent EMG without evidence for a diffuse femoral neuropathy or upper lumbar radiculopathy. In case 4, MRI of the nerve was available and revealed LFCN fusiform enlargement with T2 hyperintensity; compression and distortion of the nerve were noted during surgery. At neurectomy, 2 additional patients had focal compression at the inguinal ligament with visible distal enlargement of the LFCN (cases 2 and 3). A fourth also had visible compression at time of surgery of the LFCN at the inguinal ligament with associated erythema (case 5).

All patients had transient worsening of neuropathic pain immediately postneurectomy that subsequently improved. Sustained clinical improvement of pain postoperatively was reported in 6 out of 7 patients (follow-up period between 2 weeks and 31 months with a median follow up of 4.5 months) (table 1). Many had dramatic improvements in pain scores going from a level of 9 out of 10 preoperatively to 0 out of 10 at follow-up. Two patients were on narcotics preoperatively and were able to discontinue them (cases 1 and 3).

LFCN histopathologic findings. Gross abnormalities of the resected nerve included focal indentation (4 of 7) and enlargements distal to the indentations (2 of 7) (table 2, figure 1). All nerve biopsies had reduced fiber density with multifocal fiber loss (7 of 7), selective

Table 1 Patients with meralgia paresthetica undergoing neurectomy

Case, age, y/sex	BMI, kg/m ² (WHO classification of obesity) ^a	~ Symptom duration, y	Lateral thigh symptoms	Response to LFCN neurectomy
1, 31/F	20.14 (normal)	6	Unilateral, intermittent, worse with standing and lying down	Pain score before neurectomy 9 out of 10; at 30 months, follow-up 0 out of 10; narcotics discontinued postsurgery
2, 27/F	35.21 (obese, Class II)	2	Unilateral, continuous, worse with standing or walking	Relief of pain and dysesthesias at 3-wk follow-up; able to return to work without restrictions
3, 37/M	41.61 (obese, Class III)	2	Unilateral, continuous, worse with walking	Pain score before neurectomy "20 out of 10"; at 31 months follow-up, 4 out of 10; able to return to work and wear clothing touching thigh; narcotics discontinued postsurgery
4, 58/M	30.73 (obese, Class I)	15–20	Unilateral, now bilateral, worse with standing, improved with hip flexion	Reported relief of symptoms at 2-wk follow-up
5, 78/M	31.11 (obese, Class I)	15–20	Bilateral, left worse than right, continuous all positions, initially worse with standing	Pain score before neurectomy 9 out of 10; at 10 months follow-up, 0 out of 10; can walk, wear slacks, and stand without symptoms
6, 38/F	44.81 (obese, Class III)	2	Unilateral, continuous, worse with lying	Pain score before neurectomy 8 out of 10; at 4.5 months follow-up, 2 out of 10
7, 38/M	29.6 (preobese/obese, Class I)	3	Unilateral, continuous	One area of lateral thigh is now pain-free; another is persistently painful

Abbreviations: BMI = body mass index; LFCN = lateral femoral cutaneous nerve; WHO = World Health Organization.

^aWHO BMI calculator available at <http://apps.who.int/bmi/index.jsp>.

Table 2 Pathologic findings of lateral femoral cutaneous nerve in meralgia paresthetica

Case	Gross appearance	Interfascicular multifocal fiber loss ^a	Loss of large myelinated fibers with regeneration	Perineurial thickening and subperineurial edema	Perivascular epineurial inflammation
1	Normal	Mild to severe	Yes, thinly myelinated profiles	Diffusely thickened, subperineurial edema	No
2	Focal indentation and distal enlargement at inguinal ligament	Normal to severe (figure 1, B and C)	Yes, many fascicles with only small myelinated profiles	Focally thickened, subperineurial edema	Large ^b inflammatory collections, individual inflammatory cells endoneurial and epineurium (figure 1, G and H)
3	Longitudinal indentation and distal enlargement at inguinal ligament (figure 1A)	Normal to severe	Yes, clusters of thinly myelinated profiles	Diffusely thickened, subperineurial edema	Small ^b inflammatory collections
4	Focal indentation at inguinal ligament with nerve distortion	Moderate to severe	Yes, multifocal clusters of small, thinly myelinated profiles	Focally thickened, subperineurial edema (figure 1E)	Moderate ^b inflammatory collections (figure 1F)
5	Focal indentation at inguinal ligament with nerve erythema	Moderate to severe	Yes, loss of large myelinated fibers but no regenerative clusters	Subperineurial edema, focally thickened perineurium	Small ^b inflammatory collections
6	Normal	Moderate to severe	Yes, loss of large myelinated fibers but no regenerative clusters	Subperineurial edema, focally thickened perineurium (figure 1D)	One small ^b inflammatory collection
7	Normal	Normal to severe	Yes, loss of large myelinated fibers but no regenerative clusters	Diffusely thickened perineurium in select fascicles	No

^a Range of interfascicle fiber density involvements are described.

^b Large (>100 mononuclear cells), small (10–50 mononuclear cells) in a high-power 50× magnification field.

loss of large myelinated fibers (7 of 7), perineurial thickening (7 of 7), and Renault bodies (7 of 7). Six cases had subperineurial edema; 4 had regenerating clusters and thinly myelinated profiles.

Teased fibers preparations revealed severe loss of large fibers with primarily empty strands in 3 cases; 4 cases had grouped empty strands typical of multifocal fiber loss. Increased rates of demyelination were noted in 2 of 7 cases, as can be seen in models of chronic compression (cases 1 and 2).^{6,7} Axonal degeneration was noted in 3 cases (2, 4, and 5); each of these cases had edema and inflammatory collections.

A loss of large myelinated fibers was seen in all cases. Morphometry supported this observation, where loss of large myelinated fibers was accompanied by a shift to smaller fibers, consistent with a chronic regenerative process (figure e-1 on the *Neurology*[®] Web site at Neurology.org). Five patients had varying but abnormal degrees of intraneurial and epineurial inflammation; 1 patient had a large collection of inflammatory cells (greater than 100 cells) but had undergone neurolysis of the same nerve 3 months earlier (figure 1). Four biopsies had small (10–50 cells) and one biopsy had moderate (50–100 cells) perivascular collections. Perineurial thickening, loss of large myelinated fibers, and inflammation were not seen in the control LFC autopsied nerve.

DISCUSSION Patients with chronic MP and intractable pain have an LFCN mononeuropathy with reduced myelinated nerve fiber density. Our pathologic and operative experience supports nerve compression with


indentation at the inguinal ligament as the primary active pathogenesis. The sustained benefits seen by neurectomy would also support that mechanism. Inflammation and multifocal fiber loss associates with these findings and may suggest an additional pathogenic component.

The patients presented here have the predominant pathologic features described in animal models and autopsy series of chronic nerve compression.^{7–9} In animal models, experimental compression caused selective damage to large myelinated fibers with preservation of the small myelinated and unmyelinated fibers, similar to our patients. Also reported is demyelination and axonal degeneration under the areas of compression with axonal degeneration in the segment distal to compression as seen in several of our patients.⁶

Focal demyelination, thickened perineurium, endoneurial edema, Renault bodies, loss of large myelinated fibers with numerous thinly myelinated fibers, and regenerating clusters have been described in autopsied specimens of human ulnar nerves at sites of compression.⁸ Similar to these cases of compression, our MP cases had perineurial thickening, loss of large myelinated fibers, Renault bodies, subperineurial edema, and regenerating clusters.

We and others hypothesized that in some patients with MP inflammation may play a prominent pathologic role in MP.^{1,3} The multifocal fiber loss and inflammation seen in these cases is of note and might suggest a component of inflammation beyond a compressive etiology. Specifically, multifocal fiber loss has

Figure 1 Characteristic findings in lateral femoral cutaneous nerve biopsies from patients with chronic meralgia paresthetica who underwent neurectomy



(A) Nerve indentation was frequently seen (4 of 7 biopsies, arrow) at the site of inguinal ligament compression with associated swellings distal (arrowhead) to the compression (2 of 7 cases). Epoxy-embedded semithin sections stained with methylene blue showed (B) interfascicular and (C) intrafascicular multifocal fiber loss without selective subperineurial fiber loss and (D) perineurial thickening. (E) On Luxol fast blue/periodic acid-Schiff stain, subperineurial edema was seen. (F) Trichrome paraffin preparation of case 4 where a moderate collection of inflammatory mononuclear cells was seen within the epineurium juxtaposed to myelinated fibers (arrows). (G) Hematoxylin & eosin stain shows marked epineurial inflammation in case 2 that was 3 months post unsuccessful neurolysis of the same nerve, and (H) smooth muscle actin (SMACTIN) preparation shows evidence for vessel wall fragmentation (arrows).

most commonly been reviewed to occur in inflammatory immune processes like vasculitis.¹⁰ Among our presented patients, limited or moderate inflammation was seen in 4 of 7 cases; 1 patient had a large inflammatory collection, but in that case, the inflammation may simply relate to prior neurolysis of the same nerve (3 months prior). Although earlier experimental

work in compressive neuropathies suggested that focal compression may lead to ischemia caused by endoneurial edema, that fiber loss occurred in the subperineurial areas via a theorized “miniature compartment syndrome” mechanism.¹¹ In our cases, selective subperineurial fiber loss was not seen. We therefore theorize either chronic sustained compression or a prior significant inflammatory insult not captured at the time of biopsy as the mechanism for the pattern of nerve fiber loss. In support of an inflammatory component is the initial but unsustainable response to local steroid injection in our patients. But against a significant ongoing inflammatory process are absence of microfasciculation, neovascularization, and hemosiderin-laden macrophages typical of other nonsystemic nerve vasculitis as can specifically affect the femoral nerve in lumbosacral plexitis.¹²

Because our patients did not experience sustained benefit from steroid injection but had prolonged relief with neurectomy, a primary compressive mechanism is most strongly supported at the time of surgery. Our study has selection bias against cases where inflammatory mechanisms might predominate because such persons would be predicted to have a monophasic and self-limited course and would not come to biopsy. The majority of patients with MP do have a self-limited course.¹

The pathologic findings in patients with chronic MP combined with the clinical responsiveness to neurectomy at the sites of LFCN compression supports chronic compression as the primary cause of their pain and axonal loss. Although inflammation may play a role in some cases, it does not appear to be the primary pathogenesis in unremitting chronic cases. From this anecdotal case series, it is suggested that patients having chronic intractable pain may benefit from removal of the LFCN at the site of compression.

AUTHOR CONTRIBUTIONS

Dr. Berini: design, acquisition and analysis of data, drafting and editing the manuscript. Dr. Spinner: concept, acquisition of the data, analysis, editing the manuscript. Dr. Jentoft: acquisition of the data, analysis, editing the manuscript. J.K. Englestad: creation of the figures, editing the figures, critical edits. Dr. Staff: acquisition of data, analysis and review of the manuscript. Dr. Suanprasert: biopsy interpretation, acquisition of data, review of manuscript. Dr. Dyck: acquisition of data, critical editing of the manuscript and figures. Dr. Klein: concept and design of the study, acquisition of the data, drafting and critically editing the manuscript.

STUDY FUNDING

Supported by the National Institute of Neurologic Disorders and Stroke K08 (NS065007).

DISCLOSURE

S. Berini, R. Spinner, M. Jentoft, J. Englestad, N. Staff, N. Suanprasert, and P. Dyck report no disclosures relevant to the manuscript. C. Klein is

Received November 1, 2013. Accepted in final form January 23, 2014.

REFERENCES

1. Parisi TJ, Mandrekar J, Dyck PJ, Klein CJ. Meralgia paresthetica: relation to obesity, advanced age, and diabetes mellitus. *Neurology* 2011;77:1538–1542.
2. van Slobbe AM, Bohnen AM, Bernsen RM, Koes BW, Bierma-Zeinstra SM. Incidence rates and determinants in meralgia paresthetica in general practice. *J Neurol* 2004;251:294–297.
3. Wartenberg R. Meralgia paresthetica. *Neurology* 1956;6:560–562.
4. Dyck PJ, Dyck PJ. Pathologic alterations of nerves. In: Dyck PJ, Thomas PK, eds. *Peripheral Neuropathy*, 4th ed. 2005:737–780.
5. Shin YB, Park JH, Kwon DR, Park BK. Variability in conduction of the lateral femoral cutaneous nerve. *Muscle Nerve* 2006;33:645–649.
6. Dyck PJ, Lais AC, Giannini C, Engelstad JK. Structural alterations of nerve during cuff compression. *Proc Natl Acad Sci USA* 1990;87:9828–9832.
7. Ochoa J, Marotte L. The nature of the nerve lesion caused by chronic entrapment in the guinea-pig. *J Neurol Sci* 1973;19:491–495.
8. Neary D, Eames RA. The pathology of ulnar compression in man. *Neuropathol Appl Neurobiol* 1975;1:69.
9. Ochoa J, Danta G, Fowler TJ, Gilliatt RW. Nature of the nerve lesion caused by a pneumatic tourniquet. *Nature* 1971;233:265–266.
10. Gwathmey KG, Burns TM, Collins MP, Dyck PJ. Vasculitic neuropathies. *Lancet Neurol* 2014;13:67–82.
11. Lundborg G, Myers R, Powell H. Nerve compression injury and increased endoneurial fluid pressure: a “miniature compartment syndrome.” *J Neurol Neurosurg Psychiatry* 1983;46:1119–1124.
12. Dyck PJ, Windebank AJ. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment. *Muscle Nerve* 2002;25:477–491.

This Week's *Neurology*[®] Podcast



Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology (See p. 1556)

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 29, 2014, issue of *Neurology*. In the second segment, Dr. Joanna Suski talks with Dr. Barbara Koppel about the AAN paper on efficacy and safety of medical marijuana in selected neurologic disorders. Dr. Adam Numis reads our e-Pearl of the week about myoclonic astatic epilepsy. In the next part of the podcast, Dr. Lara Marcuse focuses her interview with Dr. Greg Bergey on epilepsy therapeutics: Beyond medications for the refractory patient.

Disclosures can be found at www.neurology.org.

At www.neurology.org, click on “RSS” in the Neurology Podcast box to listen to the most recent podcast and subscribe to the RSS feed.

CME Opportunity: Listen to this week's *Neurology* Podcast and earn 0.5 AMA PRA Category 1 CME Credits[™] by answering the multiple-choice questions in the online Podcast quiz.